Wells Fargo & Company Reiterates Equal Weight Rating for Rapt Therapeutics (NASDAQ:RAPT)

Rapt Therapeutics (NASDAQ:RAPT)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Wells Fargo & Company in a research note issued to investors on Tuesday, MarketBeat reports. They currently have a $58.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 0.79% from the company’s previous close.

A number of other equities analysts have also issued reports on the stock. Leerink Partners raised shares of Rapt Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $16.00 to $37.00 in a research report on Friday, September 26th. Leerink Partnrs upgraded Rapt Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. HC Wainwright lowered shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 target price for the company. in a report on Tuesday. Cowen downgraded shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Rapt Therapeutics from $55.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $48.22.

Rapt Therapeutics Price Performance

Shares of RAPT traded up $22.45 during mid-day trading on Tuesday, reaching $57.55. 29,611,541 shares of the company’s stock traded hands, compared to its average volume of 2,691,506. The stock’s 50-day moving average is $32.75 and its two-hundred day moving average is $23.37. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $57.61. The stock has a market cap of $1.59 billion, a P/E ratio of -5.20 and a beta of 0.45.

Rapt Therapeutics (NASDAQ:RAPT) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.23. Research analysts predict that Rapt Therapeutics will post -2.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RAPT. Invesco Ltd. grew its position in Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after buying an additional 47,391 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Rapt Therapeutics in the first quarter valued at $188,000. Dimensional Fund Advisors LP purchased a new stake in Rapt Therapeutics during the 3rd quarter worth about $231,000. Bridgeway Capital Management LLC raised its stake in Rapt Therapeutics by 32.0% in the 3rd quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock valued at $532,000 after purchasing an additional 5,000 shares during the last quarter. Finally, UBS Group AG boosted its stake in shares of Rapt Therapeutics by 680.3% during the 3rd quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after purchasing an additional 25,116 shares during the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

Trending Headlines about Rapt Therapeutics

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to buy RAPT for ~$2.2 billion (~$58.00 per share), giving RAPT shareholders a near‑term cash exit and driving the stock rally. GSK to buy RAPT Therapeutics for $2.2 billion
• Positive Sentiment: Deal rationale: GSK gains access to RAPT’s late‑stage food‑allergy treatment, supporting strategic value and justifying the takeover premium. RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition
• Neutral Sentiment: TD Cowen reaffirmed a “hold” on RAPT — a muted analyst reaction that neither amplifies nor contradicts the deal’s valuation for shareholders. Benzinga
• Neutral Sentiment: HC Wainwright downgraded RAPT from “buy” to “neutral” with a $58 price target — effectively pricing the stock at the announced deal level and implying little or no incremental upside beyond the offer. RAPT just downgraded at HC Wainwright
• Negative Sentiment: Two investor‑rights firms (Ademi LLP and Halper Sadeh LLC) launched investigations into whether the $58 per‑share sale is fair to RAPT shareholders — potential legal challenges or shareholder litigation could delay closing or pressure deal terms. Ademi investigates fairness of RAPT transaction Halper Sadeh investigates fairness of RAPT sale

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.